Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists.

Article Details

Citation

Li X, Murray WV, Jolliffe L, Pulito V

Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists.

Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. doi: 10.1016/s0960-894x(00)00169-4.

PubMed ID
10843225 [ View in PubMed
]
Abstract

A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha1a adrenergic receptor (alpha1a-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha1a-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha1-adrenergic antagonists.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
FlupentixolAlpha-1A adrenergic receptorProteinHumans
Unknown
Antagonist
Details